Marijuana Rescheduling Is Delayed. But What Are Cannabis Operators Actually Waiting For?

The latest delay

On September 29, DEA Chief Administrative Law Judge Derek C. Julius stayed the pending proceeding over the proposed transfer of marijuana from Schedule I to Schedule III. The merits hearing itself already happened, running from June 29 through July 15. But on September 28, three participants asked the tribunal to add a September 23 Government Accountability Office report to the record and permit additional briefing over its significance. The GAO report found, among other things, that DEA lacks comprehensive written policies identifying roles, responsibilities and procedures for administrative drug scheduling. GAO-26-108623

Judge Julius stayed the case while he considers that request. The government must respond by October 13, and the other participants may respond by the same deadline. The order does not decide whether the GAO report actually undermines the marijuana proceeding, nor does it tell us how long the pause ultimately will last. So, yes: a delay. But from an operator’s perspective, I think there is a more interesting question. How much does the delay actually change the endgame?

Start with 280E

For adult-use businesses, the clearest economic consequence of broader Schedule III treatment is IRC § 280E. Section 280E denies ordinary deductions and credits to a business trafficking in substances listed in Schedule I or II. Schedule III falls outside the statute. That is not a small thing. For operators carrying payroll, rent, marketing, professional fees and the dozens of other ordinary expenses that § 280E makes extraordinarily painful, eliminating it can materially change cash flow and profitability. 26 U.S.C. § 280E

If the remainder of marijuana moves to Schedule III, adult-use operators should get that same basic Schedule III tax consequence. But then what? That is where the conversation gets more complicated.

Schedule III is not the same thing as federal legalization

One of the easiest mistakes in this entire discussion is to treat a scheduling decision as though it answers the separate question of whether the existing state industry is federally lawful. It does not. The Controlled Substances Act generally requires anyone manufacturing, distributing or dispensing a controlled substance to obtain the appropriate federal registration. That requirement does not disappear because the substance is in Schedule III rather than Schedule I. 21 U.S.C. § 822

The April 2026 rescheduling order may give us a hint of what that looks like. It moved FDA-approved marijuana products and marijuana subject to state medical-marijuana licenses into Schedule III. It then added a new registration pathway under 21 C.F.R. § 1301.13(k), allowing qualifying state medical licensees to seek DEA registration as manufacturers, distributors and dispensers. The order allows DEA to rely heavily on existing state regulation and, among other things, permits state medical documentation to function within the federal dispensing framework. 21 CFR § 1301.13(k)

And the rescheduling order drew one line very clearly: those registrations do not authorize marijuana for non-medical purposes. The order expressly provides that a medical-marijuana registration does not authorize the manufacture, distribution, dispensing or use of marijuana for non-medical purposes. That sentence may end up being more important to adult-use operators than almost anything happening in the scheduling hearing.

Same schedule. Potentially very different legal status.

Imagine the broader proceeding eventually reaches the result the industry has been anticipating: the marijuana that remains in Schedule I moves to Schedule III. At that point, both state-licensed medical marijuana and adult-use marijuana could be Schedule III controlled substances. But that does not necessarily mean they occupy the same position under federal law. Medical marijuana already has a purpose-built federal registration pathway. DEA can register state-licensed manufacturers, distributors and dispensers, and the April order expressly integrates state medical regulatory systems into that federal structure. Adult use does not presently have an equivalent pathway.

The industry’s working assumption seems to be that a new and distinct pathway for adult use will be created alongside the medical one. I am not sure that assumption is safe. The alternative is that nothing separate gets built, and whatever federal structure exists for marijuana is the medical one, with adult-use activity sitting outside it. On that reading, an adult-use business could receive the tax benefit of marijuana being in Schedule III while its underlying manufacture, distribution or sale remains unauthorized under federal controlled-substances law.

That sounds strange until you remember what scheduling actually does. A schedule tells you how the federal government controls a substance. It does not necessarily tell you who is legally allowed to sell it, through what channel, to whom, or under what conditions. There are plenty of Schedule III substances. That does not mean anyone can manufacture them and open a retail store selling them for non-medical consumption.

And that brings us to the question I think operators should be asking much more frequently: is there a federal registration pathway compatible with Schedule III compliance for adult-use marijuana at all? My working assumption is that the answer is no, and that nothing in the current proceeding changes it. Right now, that answer is far less clear than the tax answer.

The medical/adult-use distinction is already important

This is especially relevant for businesses operating in states where medical and adult-use activity already overlap. Same building, same employees, sometimes the same cultivation facility, sometimes essentially the same product. But under the federal framework that exists today, the distinction between those products has enormous consequences. The April order allows a federally registered medical-marijuana dispenser to dispense to individuals authorized under state law for medical purposes. It also specifically says that the registration does not authorize non-medical activity. For a dual-licensed operator, that line already runs through the building. Broader rescheduling would not erase it; it would raise the question of which side of it each license, each inventory and each employee sits on. Those are not academic questions. Those are operating-model questions, and merely changing the number next to marijuana in the Controlled Substances Act does not answer them.

So does this latest delay matter?

Of course it does. If you are an adult-use operator paying a massive effective tax rate because of § 280E, every additional month matters. If you are building a transaction around expected tax treatment, raising capital, forecasting cash flow or deciding how aggressively to expand, timing matters. And the September 29 stay introduces a new variable into a process that has already produced plenty of them.

But I am increasingly skeptical that the industry’s biggest unanswered question is simply “when will marijuana be Schedule III?” We already have marijuana in Schedule III. State-licensed medical marijuana moved there in April. And watching that transition unfold has shown us something important: Schedule III comes with registration questions, inspections, criminal-history issues, employee-access restrictions, diversion controls, recordkeeping questions and a federal regulatory structure that state operators have never previously had to navigate. The medical side is only beginning to work through those issues. Moving adult-use marijuana to the same schedule does not make those questions disappear. It may multiply them.

What I would be asking now

For an adult-use operator, I would be planning around a different set of questions:

1. What federal registration, if any, will authorize an existing state adult-use business to continue doing what it already does?
2. Does DEA create a registration category for adult-use retailers, extend some version of the state-license deference in the medical order to adult-use licensees, or leave adult use federally unauthorized despite Schedule III status?
3. Can a dual-licensed cultivation facility operate under one DEA registration when some of its production goes to medical patients and some goes to adult-use consumers, and how will dual medical/adult-use businesses separate federally authorized activity from activity that may remain unauthorized?
4. What changes for banking, financing, insurance, bankruptcy and M&A once the substance is Schedule III but the commercial activity may still violate federal law?
5. Which existing DEA controlled-substance rules suddenly become relevant to a workforce and operating model that were built entirely under state cannabis law?

Those questions may matter more operationally than whether the final rescheduling order arrives a few weeks earlier or later.

We may be waiting for the wrong answer

For years, the cannabis industry has treated Schedule III as a destination. Maybe it is better understood as the beginning of another regulatory problem. Yes, § 280E relief is enormous. Yes, moving marijuana away from Schedule I has legal and symbolic significance. But if you operate a cannabis business, the real question is not simply what schedule marijuana occupies. It is: who can legally manufacture it? Who can distribute it? Who can sell it? To whom? Under what registration? With what records, security, employee restrictions and diversion controls?

The April rescheduling order began answering those questions for one side of the industry. The broader proceeding still has not answered them for the other, and it is not clear it ever will. So the delay matters. I am just not sure it matters for the reason everyone keeps talking about.

Attorney advertising. This article is general information, not legal advice about your situation, and reading it does not create an attorney-client relationship. Tax consequences depend on individual circumstances; consult tax counsel.